CHARLES SCHWAB INVESTMENT MANAGEMENT INC - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,324,221
-36.8%
439,102
+4.6%
0.00%
-33.3%
Q2 2023$11,589,628
+39.5%
419,610
+16.2%
0.00%0.0%
Q1 2023$8,306,634
+123.9%
361,158
+6.2%
0.00%
+200.0%
Q4 2022$3,709,629
+31.9%
340,021
+1.9%
0.00%0.0%
Q3 2022$2,813,000
+9.5%
333,643
+2.7%
0.00%0.0%
Q2 2022$2,569,000
-66.6%
324,758
-0.2%
0.00%
-50.0%
Q1 2022$7,703,000
-29.0%
325,259
+2.5%
0.00%
-33.3%
Q4 2021$10,848,000
+97.6%
317,179
+2.4%
0.00%
+50.0%
Q3 2021$5,491,000
-56.5%
309,832
+10.1%
0.00%
-50.0%
Q2 2021$12,629,000
+86.4%
281,378
+7.6%
0.00%
+100.0%
Q1 2021$6,776,000
+49.2%
261,587
+16.1%
0.00%0.0%
Q4 2020$4,541,000
+7.3%
225,220
+4.0%
0.00%0.0%
Q3 2020$4,233,000
+319.9%
216,486
+279.3%
0.00%
Q2 2020$1,008,000
+225.2%
57,072
+30.0%
0.00%
Q1 2020$310,000
+0.3%
43,904
+0.3%
0.00%
Q4 2019$309,000
-36.7%
43,753
+7.7%
0.00%
Q3 2019$488,000
+10.4%
40,614
+11.4%
0.00%
Q2 2019$442,000
+59.0%
36,469
+12.9%
0.00%
Q1 2018$278,000
-30.8%
32,315
+67.4%
0.00%
Q4 2017$402,000
+71.8%
19,300
+46.2%
0.00%
Q3 2017$234,000
+56.0%
13,2000.0%0.00%
Q2 2017$150,000
-11.8%
13,2000.0%0.00%
Q1 2017$170,000
-41.6%
13,2000.0%0.00%
Q4 2016$291,00013,2000.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders